HC Wainwright Reaffirms Buy Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $20.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 48.81% from the company’s previous close.

ENTA has been the topic of a number of other research reports. Evercore ISI decreased their price target on Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating on the stock in a research report on Monday, September 15th. Westpark Capital increased their price objective on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, September 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, October 8th. JPMorgan Chase & Co. started coverage on shares of Enanta Pharmaceuticals in a research report on Friday, November 14th. They set an “overweight” rating and a $17.00 price target on the stock. Finally, Jefferies Financial Group upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the stock from $14.00 to $20.00 in a research note on Wednesday, October 1st. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $20.33.

Enanta Pharmaceuticals Stock Down 3.2%

Shares of NASDAQ:ENTA opened at $13.44 on Friday. Enanta Pharmaceuticals has a 12-month low of $4.09 and a 12-month high of $17.15. The company’s 50 day moving average price is $13.76 and its two-hundred day moving average price is $10.42. The firm has a market cap of $387.88 million, a PE ratio of -3.51 and a beta of 0.95.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.26. Enanta Pharmaceuticals had a negative return on equity of 93.76% and a negative net margin of 125.36%.The business had revenue of $15.13 million during the quarter, compared to analysts’ expectations of $15.60 million. On average, research analysts expect that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

Insider Buying and Selling at Enanta Pharmaceuticals

In other news, insider Yat Sun Or sold 2,390 shares of the stock in a transaction on Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $34,009.70. Following the completion of the transaction, the insider directly owned 371,392 shares in the company, valued at approximately $5,284,908.16. This represents a 0.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jay R. Luly sold 4,743 shares of Enanta Pharmaceuticals stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $67,492.89. Following the sale, the chief executive officer directly owned 858,026 shares in the company, valued at $12,209,709.98. The trade was a 0.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 11,961 shares of company stock worth $170,149 over the last quarter. Corporate insiders own 13.89% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Commodore Capital LP acquired a new stake in Enanta Pharmaceuticals during the 3rd quarter worth approximately $9,576,000. Millennium Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 50.2% during the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after purchasing an additional 449,945 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 674.7% during the first quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock worth $1,971,000 after purchasing an additional 311,010 shares during the period. Man Group plc bought a new stake in shares of Enanta Pharmaceuticals in the third quarter worth $481,000. Finally, PharVision Advisers LLC acquired a new stake in Enanta Pharmaceuticals in the third quarter valued at $429,000. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.